{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:48:18Z","timestamp":1789674498973,"version":"4.0.1"},"reference-count":39,"publisher":"BMJ","issue":"10","funder":[{"DOI":"10.13039\/501100003000","name":"Stichting MS Research","doi-asserted-by":"publisher","award":["14-358e"],"award-info":[{"award-number":["14-358e"]}],"id":[{"id":"10.13039\/501100003000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1136\/jnnp-2016-313772","type":"journal-article","created":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T22:09:35Z","timestamp":1471385375000},"page":"1138-1145","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":74,"title":["MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance"],"prefix":"10.1136","volume":"87","author":[{"given":"Martijn T","family":"Wijburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit I","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Vennegoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D","family":"Roosendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine O","family":"Martins Jarnalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard MJ","family":"Uitdehaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike P","family":"Wattjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,8,16]]},"reference":[{"key":"key-10.1136\/jnnp-2016-313772-1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/WCO.0b013e32834696dd","article-title":"Risks and benefits of multiple sclerosis therapies: need for continual assessment?","volume":"24","author":"Kieseier","year":"2011","journal-title":"Curr Opin Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/cei.12206","article-title":"Requirement for safety monitoring for approved multiple sclerosis therapies: an overview","volume":"175","author":"Rommer","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"key-10.1136\/jnnp-2016-313772-3","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.24153","article-title":"Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Warnke","year":"2014","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","article-title":"Natalizumab: bench to bedside and beyond","volume":"70","author":"Rudick","year":"2013","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"key-10.1136\/jnnp-2016-313772-7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2016-313772-8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ana.20431","article-title":"JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy","volume":"57","author":"Koralnik","year":"2005","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.23973","article-title":"JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment","volume":"74","author":"Schippling","year":"2013","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00415-014-7530-5","article-title":"Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature","volume":"262","author":"Wijburg","year":"2015","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00415-015-8001-3","article-title":"Concomitant granule cell neuronopathy in patients with natalizumab-associated PML","volume":"263","author":"Wijburg","year":"2016","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2013.00011","article-title":"Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy","volume":"4","author":"Linda","year":"2013","journal-title":"Front Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acn3.114","article-title":"Outcome and survival of asymptomatic PML in natalizumab-treated MS patients","volume":"1","author":"Dong-Si","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1212\/WNL.0b013e31826846b4","article-title":"The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?","volume":"79","author":"Phan-Ba","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313772-17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp-2011-300511","article-title":"MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy","volume":"83","author":"Phan-Ba","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2016-313772-18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00415-012-6759-0","article-title":"Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab","volume":"260","author":"Mc Govern","year":"2013","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-19","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1177\/1352458513481010","article-title":"Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab","volume":"19","author":"Blinkenberg","year":"2013","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2016-313772-20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00415-014-7336-5","article-title":"Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?","volume":"261","author":"Wattjes","year":"2014","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/jnnp-2014-308630","article-title":"MRI pattern in asymptomatic natalizumab-associated PML","volume":"86","author":"Wattjes","year":"2015","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"key-10.1136\/jnnp-2016-313772-22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","article-title":"Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis\u2014establishing disease prognosis and monitoring patients","volume":"11","author":"Wattjes","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-24","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"key-10.1136\/jnnp-2016-313772-25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3174\/ajnr.A4539","article-title":"Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis","volume":"37","author":"Traboulsee","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"key":"key-10.1136\/jnnp-2016-313772-26","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1177\/1352458513510224","article-title":"The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"19","author":"Wattjes","year":"2013","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2016-313772-27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WCO.0000000000000099","article-title":"Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI","volume":"27","author":"Wattjes","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-28","article-title":"Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients","author":"Wattjes","year":"2015","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2016-313772-29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1037\/h0031619","article-title":"Measuring nominal scale agreement among many raters","volume":"76","author":"Fleiss","year":"1971","journal-title":"Psychol Bull"},{"key":"key-10.1136\/jnnp-2016-313772-30","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/jnnp-2013-304986","article-title":"Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?","volume":"84","author":"Wattjes","year":"2013","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"key-10.1136\/jnnp-2016-313772-31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"key-10.1136\/jnnp-2016-313772-33","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1148\/radiol.2015150673","article-title":"Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab: diagnostic precision with MR imaging","volume":"278","author":"Hodel","year":"2016","journal-title":"Radiology"},{"key":"key-10.1136\/jnnp-2016-313772-34","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/NEN.0b013e31825caf2c","article-title":"Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab","volume":"71","author":"Kleinschmidt-DeMasters","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-011-0900-5","article-title":"Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy","volume":"123","author":"Metz","year":"2012","journal-title":"Acta Neuropathol"},{"key":"key-10.1136\/jnnp-2016-313772-36","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1212\/WNL.0000000000002586","article-title":"Punctate pattern: a promising imaging marker for the diagnosis of natalizumab-associated PML","volume":"86","author":"Hodel","year":"2016","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2016-313772-37","first-page":"27","article-title":"Imaging findings for PML in natalizumab-treated MS patients","volume":"18","author":"Richert","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2016-313772-38","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archneurol.2009.31","article-title":"Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study","volume":"66","author":"Boster","year":"2009","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2016-313772-39","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3174\/ajnr.A2975","article-title":"Reduced diffusion in a subset of acute MS lesions: a serial multiparametric MRI study","volume":"33","author":"Eisele","year":"2012","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2016-313772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T14:03:40Z","timestamp":1601042620000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2016-313772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,16]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,9,13]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1136\/jnnp-2016-313772"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2016-313772","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,16]]}}}